Sun Pharma’s ILUMYA Gets USFDA Review Nod for Psoriatic Arthritis Indication
New Delhi: Sun Pharmaceutical Industries Limited has announced that the US Food and Drug Administration (USFDA) has accepted for review its supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab-asmn) for…